Exhibit 99.1
 | Proposed issue of securities |
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
22/11/2023
The Proposed issue is:
|  | A placement or other type of issue |
Total number of +securities proposed to be issued for a placement or other type of issue
| ASX +security code | | +Security description | | Maximum Number of
+securities to be issued |
| ATH | | ORDINARY FULLY PAID | | 362,462,762 |
Proposed +issue date
29/11/2023
Refer to next page for full details of the announcement
| Proposed issue of securities | 1/5 | |
| | Proposed issue of securities |
Part 1 - Entity and announcement details
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
| 1.2 | Registered Number Type | Registration Number |
| ABN | 37080699065 |
ATH
New announcement
| 1.5 | Date of this announcement |
22/11/2023
| 1.6 | The Proposed issue is: |
A placement or other type of issue
| Proposed issue of securities | 2/5 | |
| | Proposed issue of securities |
Part 7 - Details of proposed placement or other issue | |
| | |
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
No
Is the proposed security a ‘New class’
(+securities in a class that is not yet quoted
or recorded by ASX) or an ‘Existing class’
(additional securities in a class that is already
quoted or recorded by ASX)? | Will the proposed issue of this +security include
an offer of
attaching
+securities? |
| Existing class | No |
Details of +securities proposed to be issued
ASX +security code and description
ATH : ORDINARY FULLY PAID
Number of +securities proposed to be issued
362,462,762
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
Yes
In what currency is the cash
consideration being paid? | What is the issue price per +security? |
| AUD - Australian Dollar | AUD 0.00350 |
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
| Proposed issue of securities | 3/5 | |
| | Proposed issue of securities |
| 7C.1 | Proposed +issue date |
29/11/2023
Part 7D - Listing Rule requirements | |
| | |
| 7D.1 | Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? |
No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity’s additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
| 7D.2 | Is a party referred to in listing rule 10.11 participating in the proposed issue? |
No
| 7D.3 | Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? |
No
| 7D.4 | Will any of the +securities to be issued be subject to +voluntary escrow? |
No
Part 7E - Fees and expenses
| 7E.1 | Will there be a lead manager or broker to the proposed issue? |
Yes
| 7E.1a | Who is the lead manager/broker? |
MST Financial Services Pty Ltd
| 7E.1b | What fee, commission or other consideration is payable to them for acting as lead manager/broker? |
6% of amount raised under Placement
| 7E.2 | Is the proposed issue to be underwritten? |
No
| Proposed issue of securities | 4/5 | |
| | Proposed issue of securities |
| 7E.4 | Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue |
Part 7F - Further Information
| 7F.01 | The purpose(s) for which the entity is issuing the securities |
The use of proceeds from this financing will provide ongoing funding of Alterity’s Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital. |
| 7F.1 | Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? |
No
| 7F.2 | Any other information the entity wishes to provide about the proposed issue |
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
| Proposed issue of securities | 5/5 | |
